Northwest & Ethical Investments’s Royalty Pharma RPRX Stock Holding History

Northwest & Ethical Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-47,690	Closed	-$1.84M	–	591
2025 Q4	$1.84M	Buy	47,690 +1,292	+3%	+$49.3K	0.04%	261
2025 Q3	$1.64M	Hold	46,398	–	–	0.04%	287
2025 Q2	$1.67M	Buy	+46,398	New	+$1.54M	0.04%	273
2024 Q4	–	Sell	-27,746	Closed	-$785K	–	555
2024 Q3	$785K	Buy	27,746 +1,913	+7%	+$53K	0.02%	324
2024 Q2	$681K	Sell	25,833 -1,120	-4%	-$31K	0.02%	323
2024 Q1	$819K	Buy	26,953 +21,148	+364%	+$623K	0.02%	317
2023 Q4	$163K	Buy	+5,805	New	+$160K	0.01%	360
2023 Q3	–	Sell	-18,170	Closed	-$559K	–	400
2023 Q2	$559K	Buy	+18,170	New	+$615K	0.02%	323

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Northwest & Ethical Investments's RPRX Position: Q1 2026 in Review

Northwest & Ethical Investments sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 47,690 shares — an estimated $1.84M sold.

Northwest & Ethical Investments first reported a position in RPRX in Q2 2023 and held it in 8 quarters. The position peaked at $1.84M in Q4 2025. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Northwest & Ethical Investments reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Northwest & Ethical Investments sold 47,690 Royalty Pharma shares in Q1 2026, an estimated $1.84M.
Northwest & Ethical Investments first reported a position in Royalty Pharma in Q2 2023 and held it in 8 quarters.
Northwest & Ethical Investments's Royalty Pharma position peaked at $1.84M in Q4 2025.
592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Northwest & Ethical Investments's 13F filing for Q1 2026, filed 14 May 2026.